For the year ending 2025-12-31, SPRB had $10,154K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -38,966 |
| Stock-based compensation expense | 2,574 |
| Depreciation and amortization | 21 |
| Non-cash lease expense | 268 |
| Loss on disposal of property and equipment | 0 |
| Change in fair value of warrant liability | 3,500 |
| Prepaid expenses and other current assets | -2,447 |
| Other assets | 0 |
| Accounts payable | -352 |
| Accrued expenses and other current liabilities | -2,502 |
| Deferred revenue | 0 |
| Other liabilities | -317 |
| Net cash used in operating activities | -33,327 |
| Proceeds from issuance of common stock and warrants | 50,000 |
| Proceeds from issuance of common stock related to employee stock purchase plan | 25 |
| Proceeds from exercise of pre-funded warrants | 40 |
| Proceeds from exercise of common stock options | 5 |
| Payment of debt and equity offering costs | 3,701 |
| Repayment of term loan | 2,057 |
| Tax withholding payments on restricted stock units | 831 |
| Net cash provided by (used in) financing activities | 43,481 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 10,154 |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,788 |
| Cash, cash equivalents, and restricted cash at end of period | 48,942 |
SPRUCE BIOSCIENCES, INC. (SPRB)
SPRUCE BIOSCIENCES, INC. (SPRB)